Main public logs
Jump to navigation
Jump to search
Combined display of all available logs of Azupedia. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).
- 21:34, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/29/ja (Created page with "他の抗高血糖糖尿病医薬品とは対照的に、SGLT2阻害薬は糖新生およびケト新生を抑制するのではなく、むしろ亢進させる。SGLT2阻害薬はサーチュイン1（ひいてはPGC-1αとFGF21）を活性化するため、糖尿病の治療に用いられる他の医薬品よりもC...")
- 21:31, 12 February 2024 Fire talk contribs created page basal ganglia disease (Q20897) (wbeditentity-create:2|en: basal ganglia disease, brain disease that is characterized by dysfunction of the basal ganglia which help start and control movement)
- 21:30, 12 February 2024 Fire talk contribs created page extrapyramidal symptoms (Q20896) (wbeditentity-create:2|en: extrapyramidal symptoms, drug-induced movement disorders)
- 21:29, 12 February 2024 Fire talk contribs created page parkinsonian syndrome (Q20895) (wbeditentity-create:2|en: parkinsonian syndrome, symptoms that resemble Parkinson's disease)
- 21:25, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/28/ja (Created page with "いくつかの研究では、ダパグリフロジンはプラセボや他の活性比較薬と比較して統計学的に優れた体重減少に関連することが示されている。これは主に水分よりもカロリーの減少と関連している。")
- 21:25, 12 February 2024 Fire talk contribs created page hypotrophy (Q20894) (wbeditentity-create:2|en: hypotrophy)
- 21:24, 12 February 2024 Fire talk contribs created page atrophy (Q20893) (wbeditentity-create:2|en: atrophy, partial or complete wasting away of a part of the body)
- 21:24, 12 February 2024 Fire talk contribs created page optic atrophy (Q20892) (wbeditentity-create:2|en: optic atrophy, A disorder characterized by loss of optic nerve fibers. It may be inherited or acquired. Acquired causes include ischemia, optic nerve neuropathy, glaucoma, trauma, radiation, brain tumors, and multiple sclerosis. It leads to vision disturbances.)
- 21:21, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/27/ja (Created page with "ダパグリフロジンの体内動態はBMIや体重に明らかに影響されないため、薬物動態学的知見はBMIの高い患者にも適用できると予想される。ダパグリフロジンの作用機序から予想されるように、ダパグリフロジンは用量依存的に尿中グルコース排泄量を増加させ、単回投与で最大47g/dであっ...")
- 21:19, 12 February 2024 Fire talk contribs created page sensory nerve (Q20891) (wbeditentity-create:2|en: sensory nerve, a nerve that carries sensory information toward the central nervous system)
- 21:19, 12 February 2024 Fire talk contribs created page optic nerve (Q20890) (wbeditentity-create:2|en: optic nerve, 2nd cranial nerve; paired nerve that transmits visual information from the retina to the brain)
- 21:16, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/26/ja (Created page with "ダパグリフロジンを単回漸増投与（SAD）または反復漸増投与（MAD）した健常人と2型糖尿病患者を対象とした試験では、医薬品の薬物動態プロファイルが確認された。用量依存的な濃度で、半減期は約12～13時間、Tmaxは1～2時間であり、タンパク質結合性であるため、医薬品は速やかに吸収され、腎臓による排泄は...")
- 21:15, 12 February 2024 Fire talk contribs created page hypothalamic hormones (Q20889) (wbeditentity-create:2|en: hypothalamic hormones)
- 21:14, 12 February 2024 Fire talk contribs created page hypothalamus (Q20888) (wbeditentity-create:2|en: hypothalamus, part of diencephalon)
- 21:13, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/25/ja (Created page with "*''''C<sub>max</sub>：'''''' 薬物投与後、薬物が体内で達成する最大血清濃度 *''''t<sub>max</sub>:''''' 血漿中濃度が最大になるまでの時間 *t<sub>1/2</sub>：生物学的半減期")
- 21:12, 12 February 2024 Fire talk contribs created page nerve trunk (Q20887) (wbeditentity-create:2|en: nerve trunk)
- 21:12, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/24/ja (Created page with "| Tofogliflozin/ja (10 mg) || 97.50% || 83% || 0.75 || 6.8 || 489 ng/mL || 2900 fold |}")
- 21:12, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/23/ja (Created page with "{| class="wikitable" |+ 表2: 様々なSGLT-2阻害剤の薬物動態パラメータ |- ! 薬物名 !! 生物学的利用能 !! タンパク質結合 !! 最大（時間） !! t1/2 (hours) !! Cmax !! SGLT1に対するSGLT2選択性 |- | Canagliflozin/ja || 65% (300 mg dose) || 99% || 1–2 || 10.6 (100 mg dose); 13.1 (300 mg dose) || 1096 ng/mL (100 mg dose); 3480 ng/mL (300 mg dose) || 250 fold |- | Dapagliflozin/ja || 78% || 91...")
- 21:09, 12 February 2024 Fire talk contribs created page nerve type (Q20886) (wbeditentity-create:2|en: nerve type, metaclass for enclosed, cable-like bundle of axons in the peripheral nervous system)
- 21:09, 12 February 2024 Fire talk contribs created page optic (nerve) tract (Q20885) (wbeditentity-create:2|en: optic (nerve) tract, nerve fiber originating from the optic chiasm)
- 21:08, 12 February 2024 Fire talk contribs created page visual pathway disease (Q20884) (wbeditentity-create:2|en: visual pathway disease, Human disease)
- 21:07, 12 February 2024 Fire talk contribs created page optic nerve disease (Q20883) (wbeditentity-create:2|en: optic nerve disease, cranial nerve disease that is located in the optic nerve)
- 21:06, 12 February 2024 Fire talk contribs created page methanol poisoning (Q20882) (wbeditentity-create:2|en: methanol poisoning, hazardous chemical exposure)
- 21:04, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/22/ja (Created page with "== 薬理学 == {{Anchor|Pharmacology}} このクラスの様々な医薬品の消失半減期、バイオアベイラビリティ、タンパク質結合、時間tmaxにおける血中濃度Cmax、およびその他の薬物動態パラメータを表2に示す。これらの医薬品は不活性代謝物として尿中に排泄される。")
- 21:00, 12 February 2024 Fire talk contribs created page methane monooxygenase NADH activity (Q20881) (wbeditentity-create:2|en: methane monooxygenase NADH activity, Catalysis of the reaction: methane + NADH + H+ + O2 = methanol + NAD+ + H2O.)
- 21:00, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/21/ja (Created page with "{| class="wikitable" |+ TABLE 1: SGLTはどこで発現しているのか？ |- ! SGLT !! ヒト組織で発現 |- | SGLT1 || 腸、気管、腎臓、心臓、脳、精巣、前立腺 |- | SGLT2 || 腎臓、脳、肝臓、甲状腺、筋肉、心臓 |} SGLT1とSGLT2の活性比は、発現を定義するのに役立つかもしれない。")
- 20:58, 12 February 2024 Fire talk contribs created page aflatoxin B synthase activity (Q20880) (wbeditentity-create:2|en: aflatoxin B synthase activity, Catalyzes the reaction: 8-O-methylsterigmatocystin + 2 [reduced NADPH--hemoprotein reductase] + 2 O(2) <=> aflatoxin B + 2 [oxidized NADPH--hemoprotein reductase] + H(2)O + methanol + CO(2). Produces both aflatoxin B(1) and aflatoxin B(2).)
- 20:58, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/20/ja (Created page with "ナトリウムとグルコースは、SGLT-2タンパク質によって近位尿細管の刷子縁膜を越えて尿細管上皮細胞に共輸送される。これは尿細管と細胞の間にナトリウム勾配があるために起こる現象であり、したがってグルコースの二次的な能動輸送を提供する。グルコースはその後、内皮細胞が間質グルコース...")
- 20:57, 12 February 2024 Fire talk contribs created page primary fluorescent dioxobilin-type chlorophyll catabolite methylesterase activity (Q20879) (wbeditentity-create:2|en: primary fluorescent dioxobilin-type chlorophyll catabolite methylesterase activity, Catalysis of the reaction: H2O + primary fluorescent dioxobilin-type chlorophyll catabolite = H+ + methanol + O13(4)-desmethyl pFCC.)
- 20:56, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/19/ja (Created page with "ダパグリフロジンはSGLT-2阻害薬の一例であり、SGLTに対する競合的で高選択的な阻害薬である。SGLT-2の選択的かつ強力な阻害を介して作用し、その活性は各患者の基礎的な血糖コントロールと腎機能に基づいている。その結果、腎臓でのグルコースの再吸収が低下し、血液循環中のグルコース濃度が高いほどグルコース...")
- 20:53, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/18/ja (Created page with "細胞レベルでの作用機序はよくわかっていない。有望な利尿促進薬として、この機序を定義する研究が進行中である。しかし、グルコース部位に異なる糖が結合すると、アクセス前庭におけるアグリコンの向きに影響を与えることが示されている。そのため、アグリコンが結合すると阻害剤全体に影響を及ぼす。これらのメカニズムが相乗的...")
- 20:52, 12 February 2024 Fire talk contribs created page methane monooxygenase activity (Q20878) (wbeditentity-create:2|en: methane monooxygenase activity, Catalysis of the reaction: methane + NAD(P)H + H+ + O2 = methanol + NAD(P)+ + H2O.)
- 20:51, 12 February 2024 Fire talk contribs created page methane monooxygenase NADPH activity (Q20877) (wbeditentity-create:2|en: methane monooxygenase NADPH activity, Catalysis of the reaction: methane + NADPH + H+ + O2 = methanol + NADP+ + H2O.)
- 20:51, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/17/ja (Created page with "thumb|center|upright=3.0|ネフロンにおけるグルコースの再吸収")
- 20:50, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/16/ja (Created page with "ナトリウムグルコース共輸送体（SGLT）は、主に腎臓に存在し、血液中のグルコースバランスの維持に重要な役割を果たすタンパク質である。SGLT1とSGLT2は、このファミリーの中で最もよく知られている2つのSGLTである。SGLT2は主要な輸送タンパク質であり、糸球体濾過グルコースから循環に戻る再吸収を促進し、腎臓の...")
- 20:48, 12 February 2024 Fire talk contribs created page protein-glutamate methylesterase activity (Q20876) (wbeditentity-create:2|en: protein-glutamate methylesterase activity, Catalysis of the reaction: protein L-glutamate O(5)-methyl ester + H2O = protein L-glutamate + methanol.)
- 20:47, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/15/ja (Created page with "== 作用機序 == {{Anchor|Mechanism of action}}")
- 20:47, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/14/ja (Created page with "==メンバー== {{Anchor|Members}} これらはグリフロジンクラスの既知のメンバーである： * 米国では2023年1月にベキサグリフロジンが商品名Brenzavvyとして承認されている。 * カナグリフロジンは米国で承認された最初のSGLT2阻害薬である。2013年3月に「Invokana」の商品名で承認され、EU全域でも同名で販売されている。 * Dapagliflozin...")
- 20:39, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/13/ja (Created page with "== 相互作用 == {{Anchor|Interactions}} 2型糖尿病患者の多くは他の多くの医薬品を服用しているため、SGLT2阻害薬の相互作用は重要である。グリフロジンはサイアザイド系薬剤、ループ利尿薬および関連する利尿薬の利尿作用を増強するようであり、脱水および低血圧のリスクを高める可能...")
- 20:37, 12 February 2024 Fire talk contribs created page protein methylesterase activity (Q20875) (wbeditentity-create:2|en: protein methylesterase activity, Catalysis of the reaction: protein amino acid methyl ester + H2O = protein amino acid + methanol.)
- 20:36, 12 February 2024 Fire talk contribs created page prenylcysteine methylesterase activity (Q20874) (wbeditentity-create:2|en: prenylcysteine methylesterase activity, Catalysis of the reaction: protein C-terminal S-farnesyl-L-cysteine methyl ester + H2O = protein C-terminal S-farnesyl-L-cysteine + methanol + H+.)
- 20:36, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/12/ja (Created page with "FDA有害事象報告システムでは、SGLT2阻害薬に関連した急性腎障害のイベントの増加が報告されているが、臨床試験のデータでは、SGLT-2治療によりそのようなイベントは実際には減少している。")
- 20:33, 12 February 2024 Fire talk contribs created page pectinesterase activity (Q20873) (wbeditentity-create:2|en: pectinesterase activity, Catalysis of the reaction: pectin + n H2O = n methanol + pectate.)
- 20:32, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/11/ja (Created page with "2018年8月、FDAはSGLT2阻害薬使用患者におけるフルニエ壊疽のリスク増加について警告を発した。絶対リスクは非常に低いと考えられている。")
- 20:32, 12 February 2024 Fire talk contribs created page aclacinomycin T methylesterase activity (Q20872) (wbeditentity-create:2|en: aclacinomycin T methylesterase activity, Catalysis of the reaction: aclacinomycin T(1+) + H2O <=> 15-demethylaclacinomycin T + methanol + H+)
- 20:31, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/10/ja (Created page with "下肢切断のリスク増加はカナグリフロジンと関連しているが、異なるグリフロジンに関連するこのリスクを確認するためにはさらなるデータが必要である。欧州医薬品庁のレビューでは、カナグリフロジン、ダパグリフロジン、エンパグリフロジンを服用している患者では、下肢切断（主に足指に影響）のリス...")
- 20:29, 12 February 2024 Fire talk contribs created page diphthine methylesterase activity (Q20871) (wbeditentity-create:2|en: diphthine methylesterase activity, Catalysis of the reaction: diphthine methyl ester + H2O <=> diphthine + H+ + methanol.)
- 20:28, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/9/ja (Created page with "2015年9月、FDAはカナグリフロジン（インボカーナ）およびカナグリフロジン／メトホルミン（インボカメット）に関連し、骨密度が低下するため骨折のリスクが高まるとして警告を発した。グリフロジンとメトホルミンの併用療法は、スルホニル尿素やインスリンなどの他の2型糖尿病治療薬と比較して、低血糖のリスクを低下させる。")
- 20:27, 12 February 2024 Fire talk contribs created page polyneuridine-aldehyde esterase activity (Q20870) (wbeditentity-create:2|en: polyneuridine-aldehyde esterase activity, Catalysis of the reaction: H(2)O + polyneuridine aldehyde = 16-epivellosimine + CO(2) + methanol.)
- 20:26, 12 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/8/ja (Created page with "2015年5月、FDAはグリフロジンが糖尿病性ケトアシドーシス（DKA、体内でケトン体と呼ばれる血中酸が大量に生成される重篤な状態）のリスクを高める可能性があるとの警告を発した。グルコースの血液循環を減少させることにより、グリフロジンは糖尿病性ケトアシドーシスを引き起こす内因性インスリン分泌の...")
